Full text biomedical articles
Preparation and in Vivo Evaluation of a Dutasteride-Loaded Solid-Supersaturatable Self-Microemulsifying Drug Delivery SystemMin-Soo Kim, Eun-Sol Ha, Gwang-Ho Choo, In-Hwan Baek
Int J Mol Sci. 2015 May; 16(5): 10821â10833. Published online 2015 May 13. doi:Â 10.3390/ijms160510821
Opposing Effects of Cyclooxygenase-2 (COX-2) on Estrogen Receptor β (ERβ) Response to 5α-Reductase Inhibition in Prostate Epithelial CellsTeresa T. Liu, Melanie J. Grubisha, Krystle A. Frahm, Stacy G. Wendell, Jiayan Liu, William A. Ricke, Richard J. Auchus, Donald B. DeFranco
J Biol Chem. 2016 Jul 8; 291(28): 14747â14760. Published online 2016 May 13. doi:Â 10.1074/jbc.M115.711515
Dutasteride reduces alcohol's sedative effects in men in a human laboratory setting and reduces drinking in the natural environmentJonathan Covault, Timothy Pond, Richard Feinn, Albert J. Arias, Cheryl Oncken, Henry R. Kranzler
Psychopharmacology (Berl) Author manuscript; available in PMC 2015 Sep 1.
Published in final edited form as: Psychopharmacology (Berl). 2014 Sep; 231(17): 3609â3618. Published online 2014 Feb 21. doi:Â 10.1007/s00213-014-3487-4
Formulation of a film-coated dutasteride tablet bioequivalent to a soft gelatin capsule (Avodart®): Effect of γ-cyclodextrin and solubilizersMi-Hong Min, Jin-Hyong Park, Mi-Ran Choi, Jong-Hyun Hur, Byung-Nak Ahn, Dae-Duk Kim
Asian J Pharm Sci. 2019 May; 14(3): 313â320. Published online 2018 Oct 5. doi:Â 10.1016/j.ajps.2018.08.007
Design of a gelatin microparticle-containing self-microemulsifying formulation for enhanced oral bioavailability of dutasterideIn-hwan Baek, Eun-Sol Ha, Jin-Wook Yoo, Yunjin Jung, Min-Soo Kim
Drug Des Devel Ther. 2015; 9: 3231â3238. Published online 2015 Jun 23. doi:Â 10.2147/DDDT.S86458
Identification of New Epididymal Luminal Fluid Proteins Involved in Sperm Maturation in Infertile Rats Treated by Dutasteride Using iTRAQShu-Wu Xie, Guo-Ting Li, Li-Juan Qu, Yang Cao, Qian Wang, Jie-Yun Zhou, Rui-Hua Zhong, Xiang-Jie Guo, Yan Zhu
Molecules. 2016 May; 21(5): 602. Published online 2016 May 11. doi:Â 10.3390/molecules21050602
MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trialFrancesco Giganti, Caroline M. Moore, Nicola L. Robertson, Neil McCartan, Charles Jameson, Simon R. J. Bott, Mathias Winkler, Giulio Gambarota, Brandon Whitcher, Ramiro Castro, Mark Emberton, Clare Allen, Alex Kirkham
Eur Radiol. 2017; 27(11): 4767â4774. Published online 2017 May 18. doi:Â 10.1007/s00330-017-4858-0
A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov modelEmeka I. Udeh, Chimaobi G. Ofoha, David A. Adewole, Ikenna I. Nnabugwu
BMC Cancer. 2016; 16: 405. Published online 2016 Jul 7. doi:Â 10.1186/s12885-016-2431-x
Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasterideJosephina G. Kuiper, Irene D. Bezemer, Maurice T. Driessen, Averyan Vasylyev, Claus G. Roehrborn, Fernie J. A. Penning-van Beest, Ron M. C. Herings
BMC Urol. 2016; 16(1): 53. Published online 2016 Aug 31. doi:Â 10.1186/s12894-016-0170-6
Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostateJ Miller, TH Tarter
Clin Interv Aging. 2009; 4: 251â258. Published online 2009 Jun 9. doi:Â 10.2147/cia.s4102
Role of Hepatic Glucocorticoid Receptor in Metabolism in Models of 5αR1 Deficiency in Male MiceTracy C S Mak, Dawn E W Livingstone, Mark Nixon, Brian R Walker, Ruth Andrew
Endocrinology. 2019 Sep; 160(9): 2061â2073. Published online 2019 Jun 14. doi:Â 10.1210/en.2019-00236
The corpus cavernosum after treatment with dutasteride or finasteride: A histomorphometric study in a benign prostatic hyperplasia rodent modelMarcello H A Da Silva, Waldemar S Costa, Francisco J B Sampaio, Diogo B De Souza
Asian J Androl. 2018 Sep-Oct; 20(5): 505â510. Published online 2018 Jun 8. doi:Â 10.4103/aja.aja_28_18
A 52âweek multicenter randomized controlled study of the efficacy and safety of addâon dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study)Tomonori Yamanishi, Hirotaka Asakura, Narihito Seki, Shoji Tokunaga
Low Urin Tract Symptoms. 2019 May; 11(3): 115â121. Published online 2018 Oct 24. doi:Â 10.1111/luts.12243
Genetic variations associated with response to dutasteride in the treatment of male subjects with androgenetic alopeciaArang Rhie, Ho-Young Son, Soo Jung Kwak, Seungbok Lee, Dong Young Kim, Bark-Lynn Lew, Woo-Young Sim, Jeong-Sun Seo, Ohsang Kwon, Jong-Il Kim, Seong Jin Jo
PLoS One. 2019; 14(9): e0222533. Published online 2019 Sep 16. doi:Â 10.1371/journal.pone.0222533
5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric DisorderPedro E Martinez, David R Rubinow, Lynnette K Nieman, Deloris E Koziol, A Leslie Morrow, Crystal E Schiller, Dahima Cintron, Karla D Thompson, Khursheed K Khine, Peter J Schmidt
Neuropsychopharmacology. 2016 Mar; 41(4): 1093â1102. Prepublished online 2013 Aug 14. Published online 2015 Sep 9. doi:Â 10.1038/npp.2015.246
Controlled Release of Dutasteride from Biodegradable Microspheres: In Vitro and In Vivo StudiesXiangyang Xie, Yanfang Yang, Qiang Chi, ZhiPing Li, Hui Zhang, Ying Li, Yang Yang
PLoS One. 2014; 9(12): e114835. Published online 2014 Dec 26. doi:Â 10.1371/journal.pone.0114835
Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in ManJonathan M. Hazlehurst, Andrei I. Oprescu, Nikolaos Nikolaou, Riccardo Di Guida, Annabel E. K. Grinbergs, Nigel P. Davies, Robert B. Flintham, Matthew J. Armstrong, Angela E. Taylor, Beverly A. Hughes, Jinglei Yu, Leanne Hodson, Warwick B. Dunn, Jeremy W. Tomlinson
J Clin Endocrinol Metab. 2016 Jan; 101(1): 103â113. Published online 2015 Nov 17. doi:Â 10.1210/jc.2015-2928
Significance of intraprostatic architecture and regrowth velocity for considering discontinuation of dutasteride after combination therapy with an alpha blocker: A prospective, pilot studyTetsuya Shindo, Kohei Hashimoto, Takashi Shimizu, Naoki Itoh, Naoya Masumori
Korean J Urol. 2015 Apr; 56(4): 305â309. Published online 2015 Mar 27. doi:Â 10.4111/kju.2015.56.4.305
A population-based study of the risk of osteoporosis and fracture with dutasteride and finasterideTony Antoniou, Erin M. Macdonald, Zhan Yao, Tara Gomes, Mina Tadrous, Joanne M.-W. Ho, Muhammad M. Mamdani, David N. Juurlink, for the Canadian Drug Safety and Effectiveness Research Network
BMC Musculoskelet Disord. 2018; 19: 160. Published online 2018 May 22. doi:Â 10.1186/s12891-018-2076-9
Early dutasteride monotherapy in men with detectable serum prostate-specific antigen levels following radical prostatectomy: A prospective trialYu Seob Shin, Jea Whan Lee, Myung Ki Kim, Young Beom Jeong, Seung Chol Park
Investig Clin Urol. 2017 Mar; 58(2): 98â102. Published online 2017 Feb 15. doi:Â 10.4111/icu.2017.58.2.98
|